Aptamer Enters Licensing Agreement With Alphazyme
(RTTNews) - Aptamer Group (P0J.F, APTA.L) and Alphazyme, a Maravai LifeSciences (MRVI) company, have entered into a licensing agreement for a developed Optimer for use in hot-start PCR applications. Aptamer grants Alphazyme a non-exclusive licence for use of an enzyme-modulating Optimer in hot-start PCR and next-generation sequencing applications within Alphazyme's own products and services.
Aptamer will manufacture the Optimer for Alphazyme. The agreement provides worldwide rights to Alphazyme and includes royalty payments on sales of products, milestone payments, and a supply agreement for the manufacturing of the Optimer.
Shares of Aptamer were up 4% to GBp 0.8378 at LSE on Tuesday.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.